Citigroup Inc Capricor Therapeutics, Inc. Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 6,920 shares of CAPR stock, worth $38,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,920

Previous 29,528 76.56%

Holding current value

$38,959

Previous $293,000 82.94%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$5.94 - $11.42 $134,291 - $258,183	-22,608 Reduced 76.56%	6,920 $50,000
Q2 2025 Aug 11, 2025	SELL	$6.34 - $14.23 $410,045 - $920,339	-64,676 Reduced 68.66%	29,528 $293,000
Q1 2025 May 12, 2025	BUY	$9.49 - $16.11 $2,799 - $4,752	295 Added 0.31%	94,204 $893,000
Q4 2024 Feb 12, 2025	BUY	$12.9 - $21.99 $947,582 - $1.62 Million	73,456 Added 359.15%	93,909 $1.3 Million
Q3 2024 Nov 12, 2024	BUY	$3.56 - $15.21 $32,716 - $139,779	9,190 Added 81.59%	20,453 $311,000
Q2 2024 Aug 12, 2024	SELL	$4.63 - $7.09 $310,622 - $475,661	-67,089 Reduced 85.63%	11,263 $53,000
Q1 2024 May 10, 2024	BUY	$3.61 - $6.88 $196,939 - $375,331	54,554 Added 229.24%	78,352 $532,000
Q4 2023 Feb 09, 2024	SELL	$2.71 - $5.08 $102,419 - $191,988	-37,793 Reduced 61.36%	23,798 $116,000
Q3 2023 Nov 09, 2023	BUY	$3.42 - $7.85 $210,641 - $483,489	61,591 New	61,591 $210,000
Q2 2022 Aug 10, 2022	SELL	$2.89 - $4.51 $57 - $90	-20 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.83 - $5.68 $56 - $113	20 New	20 $0

Others Institutions Holding CAPR

# of Institutions

138

Shares Held

12.5M

Call Options Held

4.16M

Put Options Held

4.24M

View Full List

About CAPRICOR THERAPEUTICS, INC.

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $137M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

More about CAPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account